Another study revealed that lipofermata could reduce the uptake of fatty acid by polymorphonuclear myeloid-derived suppressor cells and suppress tumor progression when combined with anti-CTLA4 or anti-PD1 antibodies in lung carcinoma models (Veglia et al., 2019). The gene discussed is CTLA4; the disease is lung carcinoma.